1.Surgery: In fully resectable stage IV patients, repeated surgical resection can prolong survival, thus surgery is used as one of the adjuvant treatments. 2, chemotherapy progression: oral temozolomide (TMZ) is effective, but oxaliplatin alone is ineffective in metastatic or unresectable malignant melanoma. 3, cytokines: alpha-interferon combined with low-dose response stop or alpha-interferon combined with azathioprine + formolastine chemotherapy, the efficiency of metastatic malignant melanoma up to 30-40%. 4.Continuous cellular immunotherapy: combined with lymphocyte-deleting chemotherapy may break through tumor-specific immune tolerance with better efficacy. Dendritic cell vaccine may significantly prolong overall survival and disease progression free time. 5, monoclonal antibody: CTLA-4 is considered the most promising humanized monoclonal antibody, Anderson Cancer Center study showed that giving CTLA-4 monoclonal antibody: 10mg/month x 4 cycles, in 15 patients with stage IV malignant black, 1 CR (15 months), 2 PR (7 months), 3 SD (11.8 months). 6, molecular targeted drugs: mainly sorafenib combined with chemotherapy to achieve promising results, such as: sorafenib + azacitidine, sorafenib + temozolomide, response rate up to 65%; sorafenib + teso + carboplatin, tumor shrinkage plus stability up to 85%. 7. COX-2 inhibitors: Xilapro combined with temozolomide significantly improved the disease control rate.